Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
NCT02531633 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- October 16, 2015
- Completion date
- March 21, 2018
- Enrollment
- 161 (actual)
- Sites
- 63
Conditions
As the registry lists them; a condition with its own page is linked.